Zetagen Therapeutics Announces Oversubscribed $12.9M Series B1 Financing to Advance Breakthrough Intratumoral Therapies for Breast Cancer Zetagen Therapeutics, Inc., a privately held clinical-stage biopharmaceutical company advancing first-in-class intratumoral therapies for metastatic and primary breast cancer, today announced the successful completion…
CareDx Announces Publication of New SHORE Study Demonstrating the Prognostic Power of HeartCare® for Heart Transplant Recipients in the Journal of Heart and Lung Transplantation CareDx, Inc. (Nasdaq: CDNA), a global leader in precision medicine dedicated to improving outcomes for…
Kelonia Therapeutics Announces Late-Breaking Oral Presentation Showcasing First-in-Human Data for KLN-1010, an In Vivo BCMA CAR-T Gene Therapy, at ASH 2025 Kelonia Therapeutics, Inc., a clinical-stage biotechnology company advancing a next-generation approach to genetic medicines through in vivo gene delivery,…
AGC Biologics and AAVantgarde Forge New Manufacturing Partnership to Advance Dual-Vector Gene Therapies for Inherited Retinal Diseases Following AAVantgarde Bio’s recent completion of a successful Series B financing round, the company has taken another major step forward in advancing its…
Hercules Pharmaceuticals Announces Membership in the Healthcare Distribution Alliance and Board Appointment of Timothy Ward Hercules Pharmaceuticals (Hercules), a national leader in pharmaceutical distribution and a rapidly growing provider-aligned group purchasing organization (GPO), announced today that it has officially joined…
Boston Cell Standards Announces Landmark CASI-01 Study in Lancet: eBioMedicine Demonstrating That Calibration Transforms Accuracy and Reproducibility in HER2-Low Breast Cancer Testing Boston Cell Standards today unveiled groundbreaking findings from the CASI-01 study, newly published in Lancet: eBioMedicine, marking a…
ChristianaCare Establishes Organoid Core to Power Precision Cancer Treatment ChristianaCare’s Cawley Center for Translational Cancer Research has launched a groundbreaking organoid core—marking the first time such an advanced, patient-specific modeling platform has been established within a community cancer center program…
Nuvig Therapeutics Appoints Celia J.F. Lin, M.D., as Chief Medical Officer, Strengthening Clinical Leadership Amid Advancement of Novel Immunomodulatory Programs Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company focused on developing next-generation immunomodulatory therapeutics for patients living with inflammatory…
CorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating the Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid Tumors CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company advancing a novel gene editing platform designed to counteract drug resistance in…
Johnson & Johnson Strengthens Oncology Leadership With $3.05 Billion Acquisition of Halda Therapeutics and Its Next-Generation RIPTAC™ Platform Johnson & Johnson (NYSE: JNJ) announced that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a…
New Survey Shows NMIBC Patients Want More Inclusive Care Conversations and Greater Awareness of Emerging Treatment Options A new national survey conducted in the United States by The Harris Poll, commissioned by ImmunityBio, Inc. (NASDAQ: IBRX), has shed light on…
enGene Reports Updated LEGEND Phase 2 Data Showing 62% Complete Response Rate at Six Months for Detalimogene Voraplasmid in BCG-Unresponsive NMIBC enGene Holdings Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated preliminary…